Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
Benoit YouChristopher PurdyLarry J CopelandElizabeth M SwisherMichael A BookmanGini F FlemingRobert L ColemanLeslie M RandallKrishnansu S TewariBradley J MonkRobert S MannelJoan L WalkerFabio CappucciniDavid E CohnMahvish MuzaffarDavid G MutchAndrea E Wahner HendricksonLainie MartinOlivier ColombanRobert A BurgerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
This GOG-0218 trial investigation validates ICON-7 findings about the association between poor tumor chemosensitivity and benefit from concurrent-maintenance bevacizumab, suggesting that bevacizumab may mainly be effective in patients with poorly chemosensitive disease. Bevacizumab may be prioritized in patients with a high-risk and poorly chemosensitive disease to improve their PFS/OS (patient KELIM score calculator available on the Biomarker Kinetics website).